Literature DB >> 1470285

Effectiveness of low dose cyclosporine in acquired aplastic anaemia with severe neutropenia.

O C Leeksma1, L L Thomas, J van der Lelie, M H van Oers, A E von dem Borne, R Goudsmit.   

Abstract

Six patients with acquired aplastic anaemia were treated with cyclosporine (5 mg/kg/day) either alone or in combination with corticosteroids. A favourable response was observed in 4, including 2 patients presenting with an absolute granulocyte count of less than 0.2 x 10(9)/l. The 6th patient showed no effect after 6 wk of therapy and was thereafter successfully treated with anti-thymocyte globulin (ATG). Side effects of cyclosporine therapy were minimal (maximum follow-up 20 months). Temporary discontinuation of the drug in 1 patient resulted in a relapse which responded to reinstitution of therapy. Our results indicate that cyclosporine may be an effective, well-tolerated agent in acquired aplastic anaemia even in previously untreated patients with severe neutropenia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1470285

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  2 in total

Review 1.  Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes.

Authors:  Neal S Young
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.